MannKind CEO Is Optimistic About Near-Term Approval Of Afrezza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MannKind CEO Alfred Mann played down a regulatory delay of the company's rapid-acting inhaled recombinant insulin product Afrezza and, in response to questions, refused to acknowledge that finding a partner could be tough, during a presentation and subsequent breakout session at the J.P. Morgan Healthcare Conference on Jan. 12